Cytokines in Sjogren's syndrome: potential therapeutic targets.
The dysregulated cytokine network in Sjögren's Syndrome (SS) is reflected by local and systemic overexpression of pro-inflammatory cytokines and absent or low levels of anti-inflammatory cytokines. To date, the use of cytokine based therapies in SS has been disappointing. Oral administration of low dose interferon (IFN) alpha showed inconsistent efficacy in various studies and failed to achieve the primary endpoint in a pivotal randomised controlled trial. Similarly, neither of the two tumour necrosis factor (TNF)-alpha blockers tested (etanercept and infliximab) showed efficacy in placebo controlled trials. Although the rationale for low dose oral IFN treatment has not been firmly established, TNF blockade was based on solid preclinical data. Therefore, the reason for the lack of efficacy is unclear, but recent data suggest that unexpected biological effects of TNF antagonists may have contributed to this. Cytokines, given their central role in the pathogenesis of SS, remain attractive targets for future treatments, despite the disappointing early results. Inflammatory cytokines are obvious candidates, and agents against several of them are available or under development for other autoimmune diseases similar to SS. New candidate cytokines such as IL-17 and IL-12 and/or IL-23 may provide promising targets for SS. Additionally, as an alternative to systemic treatment, which has the risk of potentially severe side effects, the use of local cytokine directed therapy should be explored.
Roescher
Nienke
N
Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, DHHS, 10 Center Drive, Bethesda, MD 20892-1190, USA. roeschern@mail.nih.gov
Tak
Paul P
PP
Illei
Gabor G
GG
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D012859:Sjogren's Syndrome / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha
Lancet. 2008 Mar 22;371(9617):987-97
18358926
Arthritis Rheum. 2010 Feb;62(2):542-52
20112381
Immunity. 2000 Nov;13(5):715-25
11114383
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2770-5
16477017
Arthritis Rheum. 2007 Dec;56(12):3995-4004
18050196
Eur J Drug Metab Pharmacokinet. 2006 Apr-Jun;31(2):109-16
16898079
J Immunol. 2008 Aug 15;181(4):2898-906
18684981
Ann Rheum Dis. 2008 Oct;67(10):1437-43
18198195
Br J Rheumatol. 1993 Jan;32(1):52-4
8422560
Am J Vet Res. 2005 Jan;66(1):164-76
15691053
Arthritis Rheum. 2008 Mar;58(3):734-43
18311793
Arthritis Rheum. 2003 Aug 15;49(4):585-93
12910567
Hum Gene Ther. 2003 Nov 20;14(17):1605-18
14633403
Oral Dis. 2009 Nov;15(8):519-26
19519622
Am J Pathol. 2009 Sep;175(3):1167-77
19700754
Arthritis Rheum. 2004 Apr;50(4):1270-6
15077311
Genes Immun. 2009 Jun;10(4):285-96
19404300
Arthritis Rheum. 2005 Sep;52(9):2740-50
16142737
Arthritis Rheum. 2009 Jun;60(6):1785-96
19479852
Br J Rheumatol. 1990 Feb;29(1):50-2
2306573
Arthritis Rheum. 2001 Oct;44(10):2371-5
11665979
J Interferon Cytokine Res. 1998 Apr;18(4):255-62
9568728
Clin Exp Rheumatol. 1996 Jul-Aug;14(4):367-71
8871834
Curr Opin Investig Drugs. 2008 May;9(5):515-22
18465662
Eur J Immunol. 2008 Apr;38(4):1058-64
18350548
Curr Opin Immunol. 2006 Dec;18(6):670-5
17010592
Arthritis Rheum. 2004 Jul;50(7):2240-5
15248223
Ann Rheum Dis. 2006 Feb;65(2):195-200
15975969
J Interferon Cytokine Res. 1999 Aug;19(8):943-51
10476942